Synecta in future CAR-T programs
This market research assesses how additional clinical superiority data for Synecta-based CAR manufacturing would change buying behavior and tests acceptance of competitive repopulation data.
Compared with CD3/CD28 beads, Synecta has shown immune synapse formation, more balanced T-cell metabolism, improved cell killing in several preclinical models, and increased persistence in a clinical trial. We now want to test in a controlled clinical study whether Synecta activation and expansion confer superiority in CAR-T fitness in cancer patients.
Competitive repopulation means two cell populations in one patient
Each patient’s cells are used to make two comparable CAR-T products, one with Synecta and one with CD3/CD28 beads. Equal numbers are mixed and infused into the same patient. Tracking both populations over approximately six months shows which persists better under the same conditions.

Assume a positive study result
Assume that Synecta-expanded cells outcompeted the control at around the six-month time point, with statistical significance, and the results have been published in a top-tier journal. Assume we used an AB/BA cross-over design to exclude any theoretical effects of the vector barcode. Further assume that GMP Synecta is available at current activation-reagent costs plus the value of replaced materials, such as cytokines. Also assume that absolute cell yields and manufacturing feasibility are at least as good as with your current technology, and that Synecta allows some simplification of the workflow.
Open-text answers are optional and may be left blank. Please complete the applicable choice questions and scales. The final follow-up section is optional.
19 questions, shown one at a time.
